Mohammad Al-Jundi is an Endocrinology/Metabolic physician affiliated with National Institutes of Health. OpenAlex indexes 19 publications with 215 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
25500 Point Lookout Rd Dept Of
Leonardtown, MD 206502015
Telephone
301-997-1250Provider last certified this registry record 14 Jul 2021.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20251 payment
- Insulet CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
77.1%Insulin Analog24%Lantus Solostar29%Humalog Kwikpen U-10013%Basaglar Kwikpen U-10013%Insulin Lispro Kwikpen U-1009%Tresiba Flextouch U-1009%Novolog Flexpen8%Fiasp Flextouch6%Humalog Kwikpen U-2006%Tresiba Flextouch U-2005%Insulin Aspart Flexpen3%Levemir Flexpen3%Part D<11 patientsGLP-1 receptor agonist21.5%Ozempic54%Mounjaro26%Trulicity20%Part D≥49 patients+ 6 more classes in this area
Hormonal (systemic)
15.8%l-Thyroxine13.4%Levothyroxine Sodium79%Synthroid21%Part D≥59 patientsThyroid Hormone Synthesis Inhibitor2.4%Methimazole100%Part D≥14 patientsCardiovascular
7.2%Statin5.5%Atorvastatin Calcium59%Rosuvastatin Calcium41%Part D≥22 patientsACE inhibitor1%Lisinopril100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Using Fuzzy Mathematical Model in the Differential Diagnosis of Pancreatic Lesions Using Ultrasonography and Echographic Texture Analysis
Critical Reviews in Biomedical Engineering
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Edward Lakatta, MD
National Institutes of Health
Douglas Lowy, MD
National Institutes of Health
Jerome Fleg, MD
National Institutes of Health
Robert Star, MD
National Institutes of Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”